10:46 AM EST - Theratechnologies Inc. : Announced the acquisition of Katana Biopharma Inc. and its targeted oncology technology platform. Founded in 2016 by a group of renowned scientists led by Dr. Richard Béliveau, Katana developed a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. Theratechnologies Inc.
shares T.TH are trading up $0.51 at $8.77.
